1-4 of 4
Laura Strauss, PhD
Close
Sort by
Journal Articles

Myeloid-Specific SHP-2 Ablation Induces Robust Anti-Tumor Immunity That Is Not Further Enhanced By PD-1 Blockade

Anthos Christofides, MD, Natalia M Tijaro-Ovalle, MD, Halil-Ibrahim Aksoylar, PhD, Rinku Pal, MS, Abdelrahman AA Mahmoud, Laura Strauss, PhD, Nikolaos Patsoukis, PhD, Vassiliki A Boussiotis, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-138975
Published: 2020
Journal Articles

Metabolic Reprogramming of Myeloid Cells in Response to Factors of "Emergency" Myelopoiesis By Myeloid-Specific PD-1 Ablation, Regulates Myeloid Lineage Fate Commitment and Anti-Tumor Immunity

Laura Strauss, PhD, Jessica D Weaver, PhD, Rinku Pal, MS, John Asara, PhD, Nikolaos Patsoukis, PhD, Vassiliki A Boussiotis, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 14.
https://doi.org/10.1182/blood-2018-99-117438
Published: 2018
Journal Articles

PD-1 Mediates Lineage Fate Determination and Function of Myeloid Cells in Response to Tumor-Mediated "Emergency" Myelopoiesis

Laura Strauss, PhD, Jessica D Weaver, PhD, Nikolaos Patsoukis, PhD, Vassiliki A Boussiotis, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 445.
https://doi.org/10.1182/blood.V130.Suppl_1.445.445
Published: 2017
Journal Articles

CD4+ CD25 high Regulatory T Cells in Newly Diagnosed Patients with Acute Myeloid Leukemia.

Miroslaw J. Szczepanski, MD, Laura Strauss, PhD, Malgorzata Czystowska, PhD, Marta Szajnik, MD, PhD, Ann Welsh, Kenneth A. Foon, MD, Theresa L. Whiteside, PhD, Michael Boyiadzis, MD
Journal: Blood
Blood (2007) 110 (11): 2835.
https://doi.org/10.1182/blood.V110.11.2835.2835
Published: 2007